New cocktail of drugs shows promise against tough bile duct cancer
NCT ID NCT05451290
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of immunotherapy (camrelizumab), a targeted therapy (apatinib), and chemotherapy (gemcitabine and oxaliplatin) given before and after surgery for 30 people with advanced biliary tract cancer. The goal is to see if this approach can shrink tumors enough for successful removal and delay cancer return. Participants will also take a maintenance drug (tegafur) for up to a year after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab, apatinib, gemcitabine, oxaliplatin, and tegafur
- What this could lead to
- If successful, this combination could help shrink tumors before surgery and prevent recurrence afterward, potentially improving survival for people with advanced biliary tract cancer.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and it's not yet proven to be better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action antibody boost chemo against bile duct cancer?
- Morning vs. afternoon: can timing boost cancer immunotherapy?
- New cocktail of drugs shows promise for tough bile duct cancer
- New hope for bile duct cancer? keytruda and lenvima combo tested
- New combo shows promise for tough liver and bile duct cancers
- Can a common drug help cancer patients regain appetite?